CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

1. Madanat, Y.
2. Savona, M.R.
3. Sekeres, M.A.
4. Platzbecker, U.
5. Santini, V.
6. Fenaux, P.
7. Diez-Campelo, M.
8. Valcárcel, D.
9. Berry, T.
10. Dougherty, S.
11. Shah, S.
12. Sun, L.
13. Wan, Y.
14. Huang, F.
15. Navada, S.
16. Komrokji, R.S.
17. Zeidan, A.M.